A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

ClinicalTrials.gov ID: NCT06615479

Public ClinicalTrials.gov record NCT06615479. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 1:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.

Study identification

NCT ID: NCT06615479
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Industry
Enrollment: 440 participants

Conditions and interventions

Conditions

Not listed

Interventions

Not listed

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 11, 2025
Primary completion: Dec 29, 2027
Completion: Jun 21, 2032
Last update posted: Aug 17, 2026

2025 – 2032

United States locations

U.S. sites: 21
U.S. states: 16
U.S. cities: 21

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35205	Recruiting
UCLA Hematology/Oncology - Santa Monica	Los Angeles	California	90404	Recruiting
University of California, Irvine (UCI) Health - UC Irvine Medical Center	Orange	California	92868	Recruiting
Georgetown University Medical Center	Washington D.C.	District of Columbia	20007	Recruiting
Baptist MD Anderson Cancer Center	Jacksonville	Florida	32207	Recruiting
University of Miami Hospital and Clinics, Sylvester Cancer Center	Miami	Florida	33136	Recruiting
Local Institution - 0228	Orlando	Florida	32804	Withdrawn
Winship Cancer Institute, Emory University	Atlanta	Georgia	30322	Recruiting
Louisiana State University Health Sciences Shreveport	Shreveport	Louisiana	71103	Recruiting
Boston Medical Center	Boston	Massachusetts	02118	Recruiting
Local Institution - 0219	Minneapolis	Minnesota	55455	Withdrawn
Weill Cornell Medical College	New York	New York	10065	Recruiting
Local Institution - 0221	Stony Brook	New York	11794	Withdrawn
Levine Cancer Institute	Charlotte	North Carolina	28204	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
Local Institution - 0097	Philadelphia	Pennsylvania	19111	Active, not recruiting
AHN West Penn Hospital	Pittsburgh	Pennsylvania	15224	Recruiting
Local Institution - 0227	Charleston	South Carolina	29425	Withdrawn
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Huntsman Cancer Institute	Salt Lake City	Utah	84112	Recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 74 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06615479, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 17, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06615479 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →